Tag
The article discusses the advancement of therapeutic cancer vaccines using personalized mRNA technology, highlighting recent positive Phase 3 results for melanoma and ongoing trials for other cancers, with potential approvals expected by 2027.
Moderna and Merck announced the success of their mRNA cancer vaccine in a Phase 3 melanoma trial, which could establish a new personalized treatment paradigm for cancer.